PREDICTMEDIX AI Aktie

 

TORONTO, 2. Juli 2025 / IRW-Press / Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FWB: 3QP), ein führender Anbieter von Vorsorgelösungen für Künstliche Intelligenz, expandiert mit einer mobilen......

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-driven health and safety solutions, is proud to announce its participation as one of four profiled companies in an exclusive European investor roadshow spanning Budapest (Hungary), Zagreb (Croatia), and Belgrade (Serbia) from May 17 to May 21, 2025. The roadshow comes at a pivotal moment in Predictmedix AI's growth trajectory. With the company already trading on the Frankfurt Stock Exchange and having recently secured significant investment from prominent German family offices, this European tour offers a strategic platform to expand its shareholder base and deepen engagement with institutional and high-net-worth investors across the continent. “Europe is becoming an increasingly critical market for us—both from a capital markets standpoint and a commercialization perspective,” said Dr. Rahul Kushwah, COO of Predictmedix AI. “As we cont...

TORONTO, 11. April 2025 / IRW-Press / Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FWB: 3QP) (Predictmedix oder das Unternehmen), ein führender Anbieter von KI-gestützten Gesundheits- und......

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-powered health screening solutions, is pleased to announce the successful closing of the third and the final tranche of its non-brokered private placement, raising total gross proceeds of $100,000 CAD. Notably, $90,000 of the tranche was subscribed by insiders, with Sheldon Kales and Dr. Rahul Kushwah each participating for $45,000, highlighting strong internal confidence in Predictmedix's future growth and innovation. The Company issued 5,000,000 units (“Units”) at a price of $0.02 per Unit, raising $100,000 in this tranche. Each Unit consists of one common share of Predictmedix and one common share purchase warrant. Each full warrant (“Warrant”) entitles the holder to acquire an additional common share at $0.05 per share for a period of 24 months. However, if the volume-weighted average trading price of Predictmedix's common shares o...

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-powered health screening solutions, is pleased to announce the successful closing of the second tranche of its non-brokered private placement, raising total gross proceeds of $405,500. Notably, this tranche saw strong participation from two prominent German family offices, underscoring growing international confidence in Predictmedix's AI-driven innovations. The Company issued 20,275,000 units (“Units”) at a price of $0.02 per Unit, raising $405,500 in this tranche. Each Unit consists of one common share of Predictmedix and one common share purchase warrant. Each full warrant (“Warrant”) entitles the holder to acquire an additional common share at $0.05 per share for a period of 24 months. However, if the volume-weighted average trading price of Predictmedix's common shares on the CSE exceeds $0.10 for ten consecutive trading days (sta...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider of AI-powered health screening solutions, is pleased to announce the successful closing of the first tranche of its non-brokered private placement. The Company issued 16,000,000 units ("Units") at an issue price of $0.02 per Unit, raising gross proceeds of $320,000. Each Unit consists of one common share of the Company (each a "Common Share") and one Common Share purchase warrant of the Company (each full warrant, a "Warrant" and collectively the "Warrants"). Each Warrant will be exercisable at $0.05 per share for a period of 24 months, ‎provided that if, following four months and a day after the closing date, the volume weighted average trading price of the Common Shares on the CSE is at ‎‎least $0.10 per Common Share for a period of ten consecutive trading days, the expiry date of the Warrants may be ‎...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) (the “Company” or “Predictmedix”), a leading provider of rapid health screening announces a proposed non brokered private placement. The Company intends to issue (the “Offering”) of up to 50,000,000 units (each, a “Unit”) at a price of C$0.02 per Unit, for aggregate gross proceeds to the Company of up to C$1,000,000. Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company at a price of C$0.05 for a period of 24 months following the closing date of the Offering. “We are pleased to announce that the company has begun receiving commitments towards the placement,” said Dr. Rahul Kushwah, COO of Predictmedix. The net proceeds will be used for general working capital needs while also for unlocking market opportunities in the U...